Biotricity (BTCY)
(Delayed Data from NSDQ)
$1.06 USD
+0.05 (4.95%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $1.04 -0.02 (-1.89%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BTCY 1.06 +0.05(4.95%)
Will BTCY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BTCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTCY
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
BTCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Other News for BTCY
Biotricity sees 2024 revenue growth exceeding 24% year-over-year
Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Biotricity Preferred Shareholders Show Increased Commitment and Support of the Company by Converting Almost All Preferred A Shares into Restricted Common Stock
Biotricity to launch direct-to-patient cardiac screening service HeartSecure
Biotricity Announces the Upcoming Launch of the First-Ever Direct-to-Patient Cardiac Screening Service, Targeting the $1.05B Home Heart Health Market